Collegium: Pricing the Generic That Hasn't Shown Up

Reaffirmed guidance, a stock cut in half, and a January 2027 date nobody can see yet

COLL · Earnings Call · 2026-11-05

The date on the calendar

Collegium's equity has been de-rated to the point of being a referendum. The shares are down roughly 30% over the last 90 trading days in one unbroken slide, and sit about 49.5% below the December 2025 high of $49.84 — on a company worth $819 million that just printed record quarterly revenue of $216.3 million and reaffirmed full-year guidance of $825–855 million in product revenue, up 8% at the midpoint. Nothing in the transcript explains a halving. Everything in the calendar does: BELBUCA's settlement date with Teva, January 23, 2027. The sell-side asked the question the tape is asking, and it is worth quoting in full because it is the whole dossier in one sentence:

have you considered a transformational type of deal, more specifically around monetizing your underlying pain business, which seems to be putting pressure on your multiple?
Noah, Analyst · 2026-11-05

Vikram Karnani's answer was tactful and unhelpful in equal measure — "“We are always open. We are always opportunistic.” — Vikram Karnani, President and Chief Executive Officer · 2026-11-05" — which is what you say when you do not want to say anything. The odd thing is how steady the BELBUCA answer has become. CFO Colleen Tupper laid out a specific, checkable surveillance list: an FDA ANDA approval, generic pricing published in compendia, and wholesaler/distributor contracting. "“To date, we have not seen any of those signals” — Colleen Tupper, Chief Financial Officer · 2026-11-05." She has said a version of this before — in August, on the same product, citing Teva's own public statements about shifting away from low-volume opioid products, plus a potential generic launch that never materialized. BELBUCA did $57.7 million, flat year over year and flat sequentially. Reimbursement pressure across the branded long-acting opioid market is real — Xtampza fell 9% and the Nucynta franchise fell 44% — but the specific cliff the market is discounting has not produced a single observable precursor.

Azstarys and the arithmetic of a second engine

Strip out pain and the story is a franchise build. ADHD is now more than 36% of revenue, up from 19% a year ago. Jornay PM prescriptions grew 16% with prescribers at an all-time high near 33,000; Azstarys delivered $26.5 million in its first full quarter of ownership, with prescriptions up nearly 2% year over year after a prescription decline of roughly the same magnitude in 2025. Together the two products hold approximately 55% of the branded long acting methylphenidate market, with Jornay alone at about 30% share, up 6.5 points. That share number is simultaneously impressive and a reminder of the ceiling: the branded slice is dwarfed by generics, and management pegs the total ADHD market at roughly 100 million prescriptions in 2025 with almost 90% of stimulants generic. The pitch is share capture from patients dissatisfied with generic methylphenidate, sold through an expanded commercial platform — 190 reps, up from 180, calling on about 27,000 target HCPs, up from 21,000. That universe has now been re-sized twice in two years; in May the Chief Commercial Officer described "about 25,000" as the efficient limit.

about 20,000 physicians cover 1/3 of all TRxs in the country... And so we go to about 25,000. That gives us about 60% coverage of the branded market.
Scott Dreyer, Chief Commercial Officer · 2026-05-07

The most underrated disclosure on the call was about gross-to-net. Azstarys came in at 73.4%, marginally better than 74.1% in the stub quarter. Asked whether it could travel the Jornay path, Tupper was explicit that Jornay's step-down from the low-70s to the mid-60s was mostly a returns-rate flush of badly-dated inventory, and: "“I do not expect that to repeat with Azstarys, although we are confident there are incremental changes that we will make over time.” — Colleen Tupper, Chief Financial Officer · 2026-11-05" In other words, the single largest margin lever management pulled on its first ADHD asset is not transferable to the second. Azstarys growth will have to come from volume and from patient-directed consumer awareness campaigns it never had under prior ownership — spend that has a lag built in, as Karnani conceded when he said he expects Azstarys growth to "“accelerate from where the levels that it is at right now.” — Vikram Karnani, President and Chief Executive Officer · 2026-11-05"

The invoice for all of this

The financial shape is a company paying cash to buy a growth curve. Adjusted operating expenses rose 25% to $69.4 million; GAAP operating expenses rose 44%. Adjusted EBITDA fell 9% to $121.6 million and non-GAAP EPS slipped to $1.96 from $2.25 — against full-year adjusted EBITDA guidance of $445–470 million that is, in the CFO's own word, "essentially flat." The cash generation from pain still funds it: $86.5 million of operating cash flow in the quarter, $144.8 million of cash and securities, net debt near 2x adjusted EBITDA, and a $50 million accelerated repurchase running through year-end. Nothing about the capital structure is subtle — liabilities at 85.4% of assets — and neither is the valuation the market is assigning to the cash flow: 4.2x free cash flow, 1.5x revenue. There is a reason for that. R&D of $0 is not an oversight — it is the business model. Every asset has a clock, and the market is now marking the clock rather than the coupon.

What stopped being said

The quietest change is strategic vocabulary. Rare disease was a live, explicit part of the business-development script as recently as February, and still surfaced in the August Q&A: "“we are open to considering opportunities within rare disease... $300 million to $500 million peak net sales range, which is a sweet spot for us.” — Vikram Karnani, President and Chief Executive Officer · 2026-08-06" It did not appear in this quarter's top keywords and did not pass Karnani's lips on the call, where the answer to the transformational-deal question went straight back to "acquiring differentiated assets... growing them." Meanwhile the Nucynta authorized generic and net-pricing discussion — a fixation for three straight quarters — has vanished entirely, replaced by a forward-looking BELBUCA question. The generic conversation rotated from the LOE that already happened to the one that hasn't. One more absence: the roster. Ian Karp introduced only the CEO and CFO. Scott Dreyer, who fielded the commercial questions on the last four consecutive Q&As, was not on the call — so the product-positioning and prescriber-depth answers came from the CEO instead. The tension here is clean and unresolved. The transcript says there is nothing to see; the tape says there is. Both can be true at once — a settlement date is an option the counterparty owns, not a disclosure the company can make — but it is worth noting that Collegium's evidence for calm is a checklist, and checklists are falsifiable. That is the thing to watch between now and January 2027.